Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 19 October 2022, 13:01 HKT/SGT
Share:
Sirnaomics to Present Latest Developments on GalAhead(TM) Therapeutic Platform at Upcoming Industry Conferences
Sirnaomics Chief Technology Officer Dmitry Samarsky is a featured speaker at the RNA Leaders USA Congress and 18th Drug Discovery Innovation Programme

Gaithersburg, MD, USA and Suzhou BioBay, China, Oct 19, 2022 - (ACN Newswire) - Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK) a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on GalAhead(TM), a GalNAc-RNAi therapeutic platform, and its pipeline programs, at two industry conferences in Boston: the RNA Leaders USA Congress and 18th Drug Discovery Innovation Programme. The RNA Leaders USA Congress is taking place October 18-19 at The Colonnade Hotel, and the 18th Drug Discovery Innovation Programme is taking place October 26-27 at The Westin Copley Place.

RNA Leaders USA Congress Presentation Details
Presentation Title : GalAhead(TM): a novel therapeutic GalNAc-RNAi platform to downregulate single and multiple genes
Presenter: Dmitry Samarsky, Sirnaomics Chief Technology Officer
Time/Date: 02:10pm EST on Wednesday, Oct.19, 2022.
Presentation Details:
-- Introduction to GalAhead, Sirnaomics' GalNAc-RNAi therapeutic platform
-- Validation of technology in vivo and in vitro
-- Progress report on GalAhead-based programs

18th Drug Discovery Innovation Programme Presentation Details
Presentation Title: A novel therapeutic GalNAc-RNAi platform to downregulate single and multiple genes
Presenter: Dmitry Samarsky, Sirnaomics Chief Technology Officer
Time/Date: 04:00pm EST on Wednesday, Oct. 26, 2022.
Presentation Details:
-- Introduction to GalAhead, Sirnaomics' GalNAc-RNAi therapeutic platform
-- Validation of technology in vivo and in vitro
-- Progress report on GalAhead-based programs

About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at www.sirnaomics.com.

CONTACT:
Dr. Dmitry Samarsky
Chief Technology Officer, Sirnaomics
Email: DmitrySamarsky@sirnaomics.com

Investors:
Nigel Yip, MBA
Chief Financial Officer, Sirnaomics
Email: NigelYip@sirnaomics.com

Media (US):
Alexis Feinberg
Tel: +1 203 939 2225
Email: Alexis.Feinberg@westwicke.com

Media (China):
Bunny Lee
Tel: +852 3150 6707
Email: sirnaomics.hk@pordahavas.com



Topic: Press release summary Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Global Sports Brand U.S. Polo Assn. Launches in Brazil With Grupo Pasquini  
July 3, 2025 11:05 HKT/SGT
Ching Lee Holdings (3728.HK) Reports Solid and Resilient Annual Results  
July 3, 2025 11:04 HKT/SGT
TravelKon Launches Unlimited Europe eSIM Range to Keep Australians Connected over European Summer Getaway  
July 3, 2025 11:03 HKT/SGT
Fujitsu to develop ETF trading platform based on TSE's CONNEQTOR and provide it to Australian Securities Exchange  
Thursday, July 3, 2025 10:14:00 AM
AI-Powered CX, Operational Efficiency, and Smarter Journeys Redefining Strategies Across UK Enterprises: Customer Experience Live Show UK 2025 Unveils Industry Priorities  
July 3, 2025 08:59 HKT/SGT
GFEAI 2025 Concludes Successfully: PM Paetongtarn Backs Human-Centric AI, AIGPC Emerges as Regional AI Ethics Hub  
July 2, 2025 22:20 HKT/SGT
Baguio Awarded Marine Department Contract for Marine Cleansing in the Eastern Waters of Hong Kong for Approximately HK$150 million  
July 2, 2025 17:51 HKT/SGT
Mitsubishi Motors Launches the All-New Grandis for the European Market  
Wednesday, July 2, 2025 11:10:00 AM
Valuufy partners with Mainichi Future Creation Lab, Supporting New Approaches to Business Sustainability  
Wednesday, July 2, 2025 11:00:00 AM
Fujitsu launches solution to enhance customers' global supply chain resilience  
Wednesday, July 2, 2025 10:32:00 AM
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: